Becker muscular dystrophy
MONDO:0010311Becker muscular dystrophy (BMD) is a neuromuscular disease characterized by progressive muscle wasting and weakness due to degeneration of skeletal, smooth and cardiac muscle.
Also known as: BMD, Becker dystrophinopathy, Becker muscular dystrophy, Becker muscular dystrophy, X-linked recessive, Becker's muscular dystrophy, muscular dystrophy pseudohypertrophic progressive, Becker type, muscular dystrophy, Becker type, muscular dystrophy, pseudohypertrophic progressive, Becker type
27 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Hope for becker MD: new drug shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called EDG-5506 (sevasemten) in people with Becker muscular dystrophy, a muscle-weakening disease. About 260 adults and teens who were in earlier EDG-5506 studies will take the drug and be monitored for side effects a…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill aims to slow muscle damage in becker MD
Disease control OngoingThis phase 2 trial tests a daily oral drug called sevasemten (EDG-5506) in 244 adults and adolescents with Becker muscular dystrophy, a condition that causes progressive muscle weakness. The study compares the drug to a placebo to see if it can reduce muscle damage, improve walki…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New study aims to sharpen tools for tracking becker muscular dystrophy
Knowledge-focused OngoingThis 24-month observational study will follow 80 people with Becker muscular dystrophy (BMD) to better understand how the disease progresses. Researchers will measure muscle strength, walking speed, breathing, and heart function using standard tests. The goal is to identify which…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC